Correction to: Leukemia (2008) 22, 2247–2256; doi:10.1038/leu.2008.235; published online 4 September 2008
Since the publication of the above article, the authors have identified an error in the legend of Figure 4.
Survival according to soluble receptor activator of nuclear factor-κB ligand/osteoprotegerin (sRANKL/OPG ratio; –, above median; —, below median).
The correct figure and legend are shown here.
The authors apologize for any inconvenience caused.
Additional information
The online version of the original article can be found at 10.1038/leu.2008.235
Rights and permissions
About this article
Cite this article
Terpos, E., Kastritis, E., Roussou, M. et al. Erratum: The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 22, 2292 (2008). https://doi.org/10.1038/leu.2008.288
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.288
This article is cited by
-
Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis
International Journal of Hematology (2009)
